LQDA
Liquidia Corporation
$69.68
+2.77
(+4.14%)
Mkt Cap
6.20B
Volume
1,282,362
52W Range
21.15-93.61
Sector
Healthcare
Beta
0.57
EPS (TTM)
1.57 USD
P/E Ratio
44.41
Revenue (TTM)
450.91M USD
Rev Growth (5Y)
+192.5%
EPS Growth (5Y)
N/A
Company Description
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 158.32M | 14.00M | 17.49M | 15.94M | 12.85M | 739,628 | 8.07M | 2.71M | 7.26M | 13.22M |
| Net Income | (68.92M) | (130.39M) | (78.50M) | (41.02M) | (34.58M) | (59.76M) | (47.58M) | (53.14M) | (29.15M) | (15.93M) |
| EPS | -0.80 | -1.66 | -1.21 | -0.67 | -0.70 | -1.76 | -2.51 | -7.42 | -3.40 | -1.86 |
| Free Cash Flow | (40.02M) | (98.37M) | (42.85M) | (29.18M) | (34.14M) | (54.90M) | (50.13M) | (32.70M) | (26.83M) | (16.83M) |
| FCF / Share | -0.47 | -1.25 | -0.66 | -0.48 | -0.69 | -1.62 | -2.71 | -4.57 | -3.13 | -1.96 |
| Operating CF | (35.69M) | (93.42M) | (41.56M) | (28.59M) | (34.03M) | (54.14M) | (48.28M) | (31.83M) | (24.29M) | (13.95M) |
| Total Assets | 327.93M | 230.31M | 118.33M | 129.20M | 93.73M | 99.53M | 68.84M | 49.42M | 14.84M | 8.49M |
| Total Debt | 197.93M | 122.39M | 49.54M | 24.46M | 16.08M | 17.14M | 24.42M | 12.77M | 22.15M | 8.68M |
| Cash & Equiv | 190.68M | 176.48M | 83.68M | 93.28M | 57.49M | 65.32M | 55.80M | 39.53M | 3.42M | 1.44M |
| Book Value | 44.75M | 77.28M | 47.29M | 90.42M | 65.27M | 71.09M | 34.95M | 18.69M | (33.69M) | (18.25M) |
| Return on Equity | -1.54 | -1.69 | -1.66 | -0.45 | -0.53 | -0.84 | -1.36 | -2.84 | N/A | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 171.68M | 132.87M | 92.02M | 54.34M | 8.84M | 3.12M | 2.92M | 4.45M | 3.66M | 2.97M | 4.53M | 3.68M |
| Net Income | 74.72M | 52.86M | 14.55M | (3.53M) | (41.58M) | (38.37M) | (38.37M) | (23.16M) | (27.94M) | (40.93M) | (27.45M) | (15.79M) |
| EPS | 0.84 | 0.60 | 0.17 | -0.04 | -0.49 | -0.45 | -0.45 | -0.30 | -0.37 | -0.54 | -0.42 | -0.24 |
| Free Cash Flow | 69.01M | (40.02M) | 42.21M | (10.68M) | (40.54M) | (31.01M) | (25.60M) | (26.83M) | (23.95M) | (25.49M) | (16.19M) | (22.04M) |
| FCF / Share | 0.78 | -0.45 | 0.48 | -0.12 | -0.47 | -0.36 | -0.30 | -0.34 | -0.31 | -0.34 | -0.25 | -0.34 |
| Operating CF | 80.24M | (35.69M) | 44.24M | (9.77M) | (39.48M) | (30.68M) | (20.81M) | (25.08M) | (22.66M) | (24.87M) | (15.98M) | (11.56M) |
| Total Assets | 521.92M | 401.53M | 327.93M | 275.98M | 257.41M | 227.43M | 230.31M | 252.89M | 177.36M | 197.12M | 118.33M | 111.64M |
| Total Debt | 128.94M | 184.82M | 197.93M | 199.18M | 200.38M | 147.66M | 122.39M | 2.69M | 2.95M | 3.23M | 49.54M | 3.77M |
| Cash & Equiv | 284.18M | 222.79M | 190.68M | 157.50M | 173.42M | 169.76M | 176.48M | 204.37M | 133.09M | 157.86M | 83.68M | 76.22M |
| Book Value | 195.11M | 108.58M | 44.75M | 22.05M | 15.19M | 49.71M | 77.28M | 110.52M | 62.72M | 86.26M | 47.29M | 48.01M |
| Return on Equity | 0.38 | 0.49 | 0.33 | -0.16 | -2.74 | -0.77 | -0.50 | -0.21 | -0.45 | -0.47 | -0.58 | -0.33 |
LQDA News
Liquidia to Present Posters at the European Respiratory Society (ERS) 2026 Congress
Liquidia Corporation to Participate in Wells Fargo Annual Healthcare Conference
Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?
Is the Options Market Predicting a Spike in Liquidia Stock?
Liquidia Corp (LQDA) Stock Down 3.1% -- Now Undervalued? GF Score: 70/100
Liquidia: A Linear Launch Priced For Exponential Growth
Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?
Will LQDA's Differentiated PAH Approach Drive Growth?
Liquidia Corp (LQDA) Shares Fall 5.8% -- What GF Score of 70 Tells Investors
Can Yutrepia's Strong Growth Drive Liquidia's PAH Expansion?